Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127304 · ClinicalTrials.gov registry record
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 11,316
- Enrollment target
NCT05127304: Completed study, sponsored by Boehringer Ingelheim.
NCT05127304 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 11,316 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05127304 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 11,316 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
Primary Outcome
All-cause health care resource utilization. Annualized population averages of visits for each of the following categories is reported: * Ambulatory visits * Office visits * Outpatient visits * Emergency room visits * Inpatient visits * Other medical visits (included services like independent laboratory, home health, durable medical equipment, etc.) Annualized population averages of visits were calculated as: (\[sum of all visits for all individuals during the follow-up period\] / \[sum of follo
Interventions
- DEVICE Trelegy Ellipta
- DEVICE Stiolto Respimat
- DRUG Furoate/Umeclidinium/Vilanterol
- DRUG Tiotropium Bromide/Olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,316 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2022-02-03 |
What the finished NCT05127304 record still lists
NCT05127304 is an observational study that tracks outcomes without assigning an intervention. Its 11,316 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 4 interventions - of which Trelegy Ellipta is the first listed.
NCT05127304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05127304 about?
NCT05127304 is a clinical study titled "A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol". The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)...
What is the current status of trial NCT05127304?
This trial is currently completed. The enrollment target is 11,316 participants. The study started on 2021-02-26. Estimated completion is 2022-02-03.
What interventions are being tested in trial NCT05127304?
The interventions under investigation include: Trelegy Ellipta (DEVICE), Stiolto Respimat (DEVICE), Furoate/Umeclidinium/Vilanterol (DRUG), Tiotropium Bromide/Olodaterol (DRUG).
Who is sponsoring clinical trial NCT05127304?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI